ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.93 CNY | -0.50% |
|
+7.62% | -17.52% |
| 18/04 | Hisoar Pharma's Unit Passes German Health Regulator's Inspection | MT |
| 01/04 | Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024. | CI |
| Sales 2021 | 2.48B 343M 28.58B | Sales 2022 | 2.7B 373M 31.1B | Capitalization | 11.35B 1.57B 131B |
|---|---|---|---|---|---|
| Net income 2021 | 95M 13.11M 1.09B | Net income 2022 | 88M 12.15M 1.01B | EV / Sales 2021 | 4.87 x |
| Net cash position 2021 | 1.24B 172M 14.31B | Net cash position 2022 | 489M 67.49M 5.62B | EV / Sales 2022 | 4.02 x |
| P/E ratio 2021 |
137
x | P/E ratio 2022 |
140
x | Employees | 2,788 |
| Yield 2021 |
1.21% | Yield 2022 |
0.71% | Free-Float | 51.53% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.50% | ||
| 1 week | +7.62% | ||
| Current month | +5.89% | ||
| 1 month | +6.65% | ||
| 3 months | -5.57% | ||
| 6 months | -15.77% | ||
| Current year | -17.52% |
1 week
5.46
6.00
1 month
5.056.29
Current year
3.917.33
1 year
3.9110.11
3 years
3.9111.93
5 years
3.9111.93
10 years
2.9618.60
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Rui Xu
CEO | Chief Executive Officer | 47 | 01/00/01 |
Bing Yao
DFI | Director of Finance/CFO | 42 | 13/19/13 |
Jin Yun Hu
BRD | Director/Board Member | 51 | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Zhong Gong
BRD | Director/Board Member | 58 | 01/07/01 |
Guo Rui Xu
CEO | Chief Executive Officer | 47 | 01/00/01 |
Bing Yao
DFI | Director of Finance/CFO | 42 | 13/19/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 31 M€ | +3.50% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 5.93 | -0.50% | 9,919,920 |
| 25/24/25 | 5.96 | +3.65% | 9,609,300 |
| 24/24/24 | 5.75 | +2.86% | 6,210,408 |
| 23/24/23 | 5.59 | +2.57% | 6,941,300 |
| 22/24/22 | 5.45 | -1.09% | 6,364,100 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the manufacture and sale of pharmaceutical materials and dyes. The Company operates through two segments: Pharmaceutical segment and Dye segment. Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations, as well as provides customized production and supporting research and development services for international pharmaceutical companies. The Companyâs pharmaceutical products comprise antibiotic series, hypoglycemic series and cardiovascular series. Dye segment is mainly involved in the manufacture and sale of environmentally friendly reactive dyes, dye intermediates and pigment intermediates. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.52% | 1.32B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002099 Stock
